Dr. Heller’s current research interests include the design and analysis of phase 2 clinical trials, the analysis of survival data, and the investigation of biomarkers to update patient prognosis. For the analysis of phase 2 studies, he has developed a test statistic that adjusts for patient risk when the patient population is heterogeneous. This approach is applicable in targeted therapy trials, where multiple patient populations are treated under a single protocol. In survival analysis, he has developed a measure of predictive accuracy, based on the concept of explained randomness. This metric, applied to risk models with survival data, is used to determine the adequacy of a risk classification model for clinical decision making. Dr. Heller’s work with circulating tumor cells, a biomarker for metastatic disease, has demonstrated both prognostic utility and clinical utility when applied to metastatic prostate cancer patients. Dr. Heller is involved in the design and analysis of laboratory and clinical studies emanating from the Departments of Medicine, Pediatrics, and Surgery.